NPC Chief Strategy Officer | Kimpossibility Life Coach & Yoga Teacher | Biopharmaceutical & Health Policy Researcher | Public Speaker
ICER’s value assessment methods can systematically undervalue treatments, which may impact patient access to those treatments and the incentives for future innovation. I spoke with AJMC - The American Journal of Managed Care to share three recommendations to improve ICER's approach: https://lnkd.in/eqgzJUnD
PERIGEE HEALTH - a Market Access Agency | Seasoned Biotech/Healthcare Executive | Market Access Executive | Early Seed & Capital Funding Experience | Board Member
The growing specialty drug market indicates more than a shift in treatment paradigms—it's showing a profound evolution in our approach to healthcare by emphasizing personalized solutions tailored to individual needs and conditions. This trajectory tells us that medical interventions are becoming increasingly targeted, efficient, and, ultimately, more effective. This could potentially offer hope for improved outcomes and quality of life across more diverse patient populations, though the growing market doesn't inherently mean easier access for patients. #MarketAccess #SpecialtyDrugs #RareDiseases
New business models are shaking up the healthcare market. This new article breaks down the GLP-1 Market using a drug manufacturer and digital services provider to cover the entire episode of care. Well done Daniel Maley Dylan Reid(Moskowitz) Robert Horne The Alliance for Artificial Intelligence in Healthcare (AAIH) https://lnkd.in/ehnm7q4m
Our recent deep dive into the impact of GLP-1 on pharma and medtech revealed some eye-opening insights: In specific therapeutic domains, we identified over 20% of revenue at risk. When we turned our focus to US providers, we uncovered a staggering 60% profit risk. Our report, based on the latest medical research, highlights key strategic steps to reduce the impact of this looming threat. What should we look at next? Authors: Chris Paddison, Betty Pio, Cian Wade, and Amelia Whitworth
Emerging tech. Spiraling medication prices. Tailored patient experiences. What's in the cards for #lifesciences in 2024? Explore the latest trends in Deloitte Global's all-new #LSOutlook24 report.
White Paper - Preparing for the At-Home Diagnostic Testing Revolution ixlayer At-home diagnostic testing is at the forefront of digital healthcare trends and has expanded exponentially across health issues. So, why should biopharma companies get involved in at-home testing and what are best practices to ensure success? Read Now: https://lnkd.in/dC9bQTvS
I'm excited to share another great report. If you want a detailed look at how employers and health plans are approaching GLP-1s plus other timely drug benefit design and management insights, check it out!
The 2024 Trends in Drug Benefit Design report is now available! Be sure to download it in preparation for our 6/18 webinar, where PSG industry experts Michael Medel and Morgan Lee will provide key insights from the report! Thank you to our report co-sponsor, Prescryptive Health, Inc.. https://lnkd.in/gJdVbExe
Using captive funding strategies to help CFOs/HR reduce medical plan cost, improve benefit plans and implement long-term strategy with measurable results.
EPIC's PSG has released their 2024 Trends in Drug Benefit Design Report. Hot topics include - GLP-1s, unbundling PBMs, CGT, increased transparency. Download the report, review and then join the webinar on June 18th for key insights. #pbm #employeebenefits #medicalinsurance #selffundedplans #captives
The 2024 Trends in Drug Benefit Design report is now available! Be sure to download it in preparation for our 6/18 webinar, where PSG industry experts Michael Medel and Morgan Lee will provide key insights from the report! Thank you to our report co-sponsor, Prescryptive Health, Inc.. https://lnkd.in/gJdVbExe
Emerging tech. Spiraling medication prices. Tailored patient experiences. What's in the cards for #lifesciences in 2024? Explore the latest trends in Deloitte Global's all-new #LSOutlook24 report.
Emerging tech. Spiraling medication prices. Tailored patient experiences. What's in the cards for #lifesciences in 2024? Explore the latest trends in Deloitte Global's all-new #LSOutlook24 report.
Biopharma Entrepreneur helping companies value assets, refine business cases for investor funding, and make evidence based decisions.
A fantastic perspective on the value of real world studies to inform ‘brand choice.’ Claims and EMR data, combined with analytics, has proven to be overwhelmingly impactful to both clinicians and the biotech industry. This analysis, specific to the weight loss market, demonstrates not just how affective 2 different medications may be but also provides insights into different patient segments associated with each brand. https://lnkd.in/eUr8Ep6f https://lnkd.in/exSgTfH4 and Relevance In this,differences in other important outcomes. #weightloss #insights #EHR
